Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
University of Pittsburgh
University of Pittsburgh
Elicio Therapeutics
Merck Sharp & Dohme LLC
Alaunos Therapeutics
Zymeworks BC Inc.
Symphogen A/S
Celldex Therapeutics
Jules Bordet Institute
NextCure, Inc.
Klus Pharma Inc.
Xencor, Inc.
Quadriga Biosciences, Inc.
Xencor, Inc.
AbbVie
AbbVie
AstraZeneca